GlobeStar Therapeutics Corp: 10-Q/A filed 2012-09-20

Name: GlobeStar Therapeutics Corp: 10-Q/A filed 2012-09-20
Creator: GlobeStar Therapeutics Corp

What GlobeStar Therapeutics Corp reported in its quarterly report amendment filed 2012-09-20 (fiscal Q3 2012): 15 published measures, 46 facts as tagged in accession 0001161697-12-000730.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form: 10-Q/A (quarterly report amendment)
Filed: 2012-09-20
Fiscal period: fiscal Q3 2012
Accession: 0001161697-12-000730 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GlobeStar Therapeutics Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-06-30	282,906	USD
At 2011-09-30	21,942	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2012-06-30	-268,528	USD
At 2011-09-30	-9,683	USD
At 2010-09-30	6,922	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-06-30	2,142	USD
At 2011-09-30	21,942	USD
At 2011-06-30	48,342	USD
At 2010-09-30	8,922	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	-722,217	USD	91
2011-10-01 to 2012-06-30	-893,845	USD	274
2010-09-16 to 2012-06-30	-950,028	USD	654
2010-10-01 to 2011-09-30	-54,105	USD	365
2011-04-01 to 2011-06-30	-17,429	USD	91
2010-10-01 to 2011-06-30	-21,680	USD	273
2010-09-16 to 2010-09-30	-2,078	USD	15

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2011-10-01 to 2012-06-30	-235,960	USD	274
2010-09-16 to 2012-06-30	-288,518	USD	654
2010-10-01 to 2011-06-30	-23,080	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2011-10-01 to 2012-06-30	496,924	USD	274
2010-09-16 to 2012-06-30	571,424	USD	654
2010-10-01 to 2011-06-30	62,500	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2011-10-01 to 2012-06-30	-280,764	USD	274
2010-09-16 to 2012-06-30	-280,764	USD	654

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2012-06-30	-950,028	USD
At 2011-09-30	-56,183	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	-722,217	USD	91
2011-10-01 to 2012-06-30	-893,845	USD	274
2010-09-16 to 2012-06-30	-950,028	USD	654
2011-04-01 to 2011-06-30	-17,429	USD	91
2010-10-01 to 2011-06-30	-21,680	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-06-30	2,142	USD
At 2011-09-30	21,942	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-06-30	551,434	USD
At 2011-09-30	31,625	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-06-30	13,700,000	shares
At 2011-09-30	12,000,000	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-06-30	680,130	USD
At 2011-09-30	45,300	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-04-01 to 2012-06-30	722,217	USD	91
2011-10-01 to 2012-06-30	893,845	USD	274
2010-09-16 to 2012-06-30	950,028	USD	654
2011-04-01 to 2011-06-30	17,429	USD	91
2010-10-01 to 2011-06-30	21,680	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2010-09-16 to 2012-06-30	46,500	USD	654
2010-10-01 to 2011-06-30	25,000	USD	273

Inspect the source

Entity: GlobeStar Therapeutics Corp / CIK 0001502152
Captured: 2026-09-21T17:19:31.788Z
SEC response SHA-256: 6be36a03e8f75354b6b3cf653d7b4e1bb0d8a85378e8b575eedf967d0fac66f7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001502152.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))